Source: BioPortfolio

Biopharma: Encorafenibbased Regimens Provide Improved PFS and OS in DifficulttoTreat BRAFMutant Colorectal Cancer Compared to Historical Benchmarks

BOULDER Colo. June 4 2016 PRNewswire &160;Array BioPharma Nasdaq ARRY announced today updated results from a Phase 2 study of the combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAFmutant colorectal cancer ...

Read full article »
Est. Annual Revenue
Est. Employees
CEO Avatar


Update CEO

CEO Approval Rating

- -/100

Biopharma is a Private company. Biopharma has an estimated revenue of <$1M and an estimate of less <10 employees.